Rapid response

  • Allows for rapid adjustment of depth of analgesia1
    Continuous infusions of Remi* should be administered only by an infusion device. The injection site should be close to the venous cannula and all IV tubing should be cleared at the time of discontinuation of infusion. Interruption of an infusion of Remi will result in rapid offset of effect1

Rapid recovery

  • Facilitates rapid recovery with no accumulation regardless of infusion duration1
    Due to the rapid offset of action of Remi, no residual analgesic activity will be present within 5 to 10 minutes after discontinuation. For patients undergoing surgical procedures where postoperative pain is generally anticipated, alternative analgesics should be administered prior to discontinuation of Remi. The choice of analgesic should be appropriate for the patient's surgical procedure and the level of follow-up care1

Added characteristics of ULTIVA

  • Well-established hemodynamic profile1
    In premedicated patients undergoing anesthesia, 1-minute infusions of
    <2 mcg/kg of Remi cause dose-dependent hypotension and bradycardia. When appropriate, bradycardia and hypotension can be reversed by reduction of the rate of infusion of Remi or the dose of concurrent anesthetics, or by the administration of fluids or vasopressors1
  • Rapid onset, offset, and recovery for predictable control of responsiveness1
  • Helps improve surgical conditions and reduce bleeding to improve surgical visibility2,3
  • Can help achieve deliberate hypotension2
  • Rapid recovery with no accumulation regardless of infusion duration1
*

Remifentanil is commonly referred to as Remi by anesthesia providers.

Compared with balanced anesthesia, Remi may result in hypotension.2

FESS = functional endoscopic sinus surgery.

FESS case study

31-year-old male

5'8'', 72 kg (158 lb)

BMI 23.8 kg/m2

Comorbidities

  • Hypertension
  • Chronic seasonal rhinitis

Medications: ACE inhibitor, antihistamine, corticosteroid (nasal)

Remifentanil is contraindicated for epidural or intrathecal administration and in patients with known hypersensitivity to fentanyl analogs.

This case study is for illustrative and educational purposes only. The dosing regimen is specific to this case study and other regimens may vary depending on patient and procedure. Any use of this product is subject to the judgment of the practitioner in each case. Please consult the full Prescribing Information in the use of this product.

 


 

Goal: predictable control

Characteristics of ULTIVA in FESS include:

See also:

  1. ULTIVA [package insert]. Rockford, IL: Mylan Institutional LLC; 2016.
  2. Eberhart LH, Folz BJ, Wulf H, Geldner G. Intravenous anesthesia provides optimal surgical conditions during microscopic and endoscopic sinus surgery. Laryngoscope. 2003;113(8):1369-1373.
  3. Wormald PJ, van Renen G, Perks J, Jones JA, Langton-Hewer CD. The effect of the total intravenous anesthesia compared with inhalational anesthesia on the surgical field during endoscopic sinus surgery. Am J Rhinol. 2005;19(5):514-520.
  4. Guy J, Hindman BJ, Baker KZ, et al. Comparison of remifentanil and fentanyl in patients undergoing craniotomy for supratentorial space-occupying lesions. Anesthesiology. 1997;86(3):514-524.